Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: A 1-year prospective multicenter study

Roberto Attanasio, Roberto Lanzi, Marco Losa, Ferdinando Valentini, Franco Grimaldi, Ernesto De Menis, Maria Vittoria Davì, Claudia Battista, Roberto Castello, Nadia Cremonini, Paola Razzore, Francesca Rosato, Marcella Montini, Renato Cozzi

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate the safety and effectiveness of lanreotide Autogel on growth hormone and insulinlike growth factor 1 (IGF-1) concentrations and tumor size in patients with acromegaly. Methods: Between September 2004 and March 2006, patients with active acromegaly who had not previously been treated with somatostatin analogues or received irradiation were enrolled in a 1-year, prospective, open, multicenter study. Lanreotide Autogel was injected subcutaneously starting with 90 mg every 4 weeks for 2 cycles and then individually titrated, aiming for safe growth hormone concentrations (3 (range, 115-7737 mm3) to 1461 mm3 (range, 63-6217 mm3) (both P

Original languageEnglish
Pages (from-to)846-855
Number of pages10
JournalEndocrine Practice
Volume14
Issue number7
Publication statusPublished - Oct 2008

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: A 1-year prospective multicenter study'. Together they form a unique fingerprint.

Cite this